Market Overview

Exact Sciences' Cologuard Included as Alternative Screening Test under Draft USPSTF Guidelines

Share:

Exact
Sciences (Nasdaq: EXAS) issued the following statement today
following the U.S. Preventive Services Task Force (USPSTF) draft
recommendation statement for colorectal cancer screening.

USPSTF included Cologuard in the draft guidelines as an alternative
screening test, along with CT colonography. The draft guidelines
recommend an "A" rating for colorectal cancer screening starting at age
50 and continuing until age 75. Screening for individuals age 75 through
85 is graded a "C." This approach represents a change from the 2008
recommendations, which assigned specific grades for different tests,
including an "I" rating for stool-based DNA.

Cologuard is a non-invasive, FDA-approved colorectal cancer screening

See full press release

Posted-In: News Contracts Press Releases

 

Related Articles (EXAS)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Novocure Announces FDA Approves Optune in Combination with Temozolomide for Treatment of Newly Diagnosed Glioblastoma

Benzinga's M&A Chatter for Monday October 5, 2015